LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Abiraterone for the treatment of metastatic castration-resistant prostate cancer that has progressed on or after a docetaxel-based chemotherapy regimen

ثبت نشده
چکیده

It is estimated that around 55-60% of men with prostate cancer will develop metastatic disease, most commonly involving bone. The initial treatment for metastatic disease is hormonal ablation, either with surgery (bilateral orchidectomy) or medically with gonadotrophin releasing hormone analogues such as goserelin, leuprorelin or triptorelin. A luteinising hormone-releasing hormone (LHRH) antagonist is also now available (degarelix) – this avoids the initial testosterone flare that is seen with the agonists. Although most patients will initially respond to this type of therapy, the disease usually progresses in the presence of castrate levels of testosterone after around 12-18 months and alternative treatment strategies are then required. The cancer may respond to additional hormonal strategies, but ultimately the cancer becomes unresponsive to further conventional hormonal manipulation.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

A Systematic Review of Clinical Practice Guidelines for Castration-Resistant Prostate Cancer

Cancer constitutes a huge burden on societies in countries with any level of economic development. Prostate cancer is the first most diagnosed cancer of men in developed countries and the forth one in developing countries in terms of incidence rate. It is also the third incident cancer of men in Iran along with a prevalence of about 10,000 cases. Castration-resistant prostate cancer (CRPC) is a...

متن کامل

A Systematic Review of Clinical Practice Guidelines for Castration-Resistant Prostate Cancer

Cancer constitutes a huge burden on societies in countries with any level of economic development. Prostate cancer is the first most diagnosed cancer of men in developed countries and the forth one in developing countries in terms of incidence rate. It is also the third incident cancer of men in Iran along with a prevalence of about 10,000 cases. Castration-resistant prostate cancer (CRPC) is a...

متن کامل

Abiraterone: A Review of its Pharmacokinetic, Pharmacodynamic Profile and Clinical Efficacy

Prostate cancer is a common cancer and it causes significant morbidity and mortality in elderly males. Management for metastatic castration resistant prostate cancer has improved tremendously over the last decade with newer agents improving overall survival and quality of life of patients. Until recently, docetaxel was the only agent to show an improvement in overall survival in patients with m...

متن کامل

Systemic Medical Treatment in Men with Metastatic Castration-Resistant Prostate Cancer: Recommendations for Daily Routine.

The approval or clinical evaluation of several new agents - cabazitaxel, abiraterone acetate, enzalutamide, sipuleucel-T, and radium-223 - has significantly changed the management of patients with metastatic castration-resistant prostate cancer (mCRPC) prior to or after docetaxel-based chemotherapy. All of these agents have resulted in a significant survival benefit as compared to their control...

متن کامل

Taxane Chemotherapy for Hormone-Naïve Prostate Cancer with Its Expanding Role as Breakthrough Strategy

Historically, androgen-deprivation therapy (ADT) was the only primary treatment for metastatic prostate cancer. After prostate cancer develops into castration-resistant prostate cancer (CRPC), there are a few life-prolonging drugs, including taxanes, such as docetaxel and cabazitaxel, as well as novel androgen receptor-targeting agents, such as abiraterone acetate and enzalutamide, which have b...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2012